Genmab to Participate in a Fireside Chat at the Citi Global Healthcare Conference in Miami

Media ReleaseCOPENHAGEN, Denmark; November 24, 2025 Genmab A/S (Nasdaq:GMAB)announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Citi Global Healthcare Conference in Miamiat 9:45 AMEST(3:45PMCET)on December 4 , 2025 .  A webcast of the fireside chat will be available on Genmab’s website athttps://ir.genmab.com/events-presentations. About Genmab   Genmab is an...

Valby, 24/11/2025 (informazione.news - comunicati stampa - salute e benessere)

A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-presentations.

 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines . 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

Media Release no. 25
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment